Fierce Biotech Releases 2022 Fierce 15 List

Every year, Fierce Biotech highlights 15 biotechs that excel in innovation, achievements, and potential. In this year’s Fierce 15, Fierce Biotech focused on finding biotechs who led the way in diversity in management and geographical regions. The companies featured target cancer, currently untreatable genetic disorders, and more with technologies ranging from small molecules to RNA.

According to Fierce, the first on the list (alphabetical) is Agomab Therapeutics, “The company has quietly been on the radar of many pharmas over its short life, CEO Tim Knotnerus noted in an interview. But it was Pfizer, flush with COVID cash, that in 2022 became its first major pharma backer. Pfizer led the European biotech’s latest series B extension round of $40.5 million while also offering up its immense clinical experience to help with AGMB-129. You don’t grab the attention of Pfizer, which has the cash and the know-how to back pretty much anything it wants, without good reason.”

To read more, click here.

(Source: Fierce Biotech, September 12^th, 2022)